These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18713991)

  • 1. Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.
    Kawamura K; McLaughlin KA; Weissert R; Forsthuber TG
    J Immunol; 2008 Sep; 181(5):3202-11. PubMed ID: 18713991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
    Ito K; Bian HJ; Molina M; Han J; Magram J; Saar E; Belunis C; Bolin DR; Arceo R; Campbell R; Falcioni F; Vidović D; Hammer J; Nagy ZA
    J Exp Med; 1996 Jun; 183(6):2635-44. PubMed ID: 8676084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.
    Valli A; Sette A; Kappos L; Oseroff C; Sidney J; Miescher G; Hochberger M; Albert ED; Adorini L
    J Clin Invest; 1993 Feb; 91(2):616-28. PubMed ID: 7679413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells.
    Forsthuber TG; Shive CL; Wienhold W; de Graaf K; Spack EG; Sublett R; Melms A; Kort J; Racke MK; Weissert R
    J Immunol; 2001 Dec; 167(12):7119-25. PubMed ID: 11739534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive TCR responses to self antigens presented by different MHC class II molecules.
    Mycko MP; Waldner H; Anderson DE; Bourcier KD; Wucherpfennig KW; Kuchroo VK; Hafler DA
    J Immunol; 2004 Aug; 173(3):1689-98. PubMed ID: 15265898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.
    Muraro PA; Vergelli M; Kalbus M; Banks DE; Nagle JW; Tranquill LR; Nepom GT; Biddison WE; McFarland HF; Martin R
    J Clin Invest; 1997 Jul; 100(2):339-49. PubMed ID: 9218510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.
    Vergelli M; Kalbus M; Rojo SC; Hemmer B; Kalbacher H; Tranquill L; Beck H; McFarland HF; De Mars R; Long EO; Martin R
    J Neuroimmunol; 1997 Aug; 77(2):195-203. PubMed ID: 9258250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).
    Kaushansky N; Altmann DM; David CS; Lassmann H; Ben-Nun A
    J Neuroinflammation; 2012 Feb; 9():29. PubMed ID: 22316121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls.
    Minohara M; Ochi H; Matsushita S; Irie A; Nishimura Y; Kira J
    Tissue Antigens; 2001 May; 57(5):447-56. PubMed ID: 11556969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hla-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice.
    Kawamura K; Yamamura T; Yokoyama K; Chui DH; Fukui Y; Sasazuki T; Inoko H; David CS; Tabira T
    J Clin Invest; 2000 Apr; 105(7):977-84. PubMed ID: 10841661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501.
    de Rosbo NK; Kaye JF; Eisenstein M; Mendel I; Hoeftberger R; Lassmann H; Milo R; Ben-Nun A
    J Immunol; 2004 Jul; 173(2):1426-35. PubMed ID: 15240739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential.
    Huh J; Yao K; Quigley L; Ludwin SK; McFarland HF; Muraro PA; Martin R; Ito K
    J Neuroimmunol; 2004 Jun; 151(1-2):94-102. PubMed ID: 15145608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separation of complexes of major histocompatibility class II molecules and known antigenic peptide by metal chelate affinity chromatography.
    Nag B; Mukku PV; Arimilli S; Kendrick T; Deshpande SV; Sharma SD
    J Immunol Methods; 1994 Mar; 169(2):273-85. PubMed ID: 7510762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.
    Kort JJ; Kawamura K; Fugger L; Weissert R; Forsthuber TG
    J Neuroimmunol; 2006 Apr; 173(1-2):23-34. PubMed ID: 16386804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model.
    Ellmerich S; Mycko M; Takacs K; Waldner H; Wahid FN; Boyton RJ; King RH; Smith PA; Amor S; Herlihy AH; Hewitt RE; Jutton M; Price DA; Hafler DA; Kuchroo VK; Altmann DM
    J Immunol; 2005 Feb; 174(4):1938-46. PubMed ID: 15699121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys.
    Meinl E; t Hart BA; Bontrop RE; Hoch RM; Iglesias A; de Waal Malefyt R; Fickenscher H; Müller-Fleckenstein I; Fleckenstein B; Wekerle H
    Int Immunol; 1995 Sep; 7(9):1489-95. PubMed ID: 7495756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
    Wucherpfennig KW; Sette A; Southwood S; Oseroff C; Matsui M; Strominger JL; Hafler DA
    J Exp Med; 1994 Jan; 179(1):279-90. PubMed ID: 7505801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.
    Pette M; Fujita K; Wilkinson D; Altmann DM; Trowsdale J; Giegerich G; Hinkkanen A; Epplen JT; Kappos L; Wekerle H
    Proc Natl Acad Sci U S A; 1990 Oct; 87(20):7968-72. PubMed ID: 1700423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes.
    Finn TP; Jones RE; Rich C; Dahan R; Link J; David CS; Chou YK; Offner H; Vandenbark AA
    J Neurosci Res; 2004 Oct; 78(1):100-14. PubMed ID: 15372502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-specific variation in the degeneracy of major histocompatibility complex (MHC) restriction.
    Carmichael P; Copier J; So A; Lechler R
    Hum Immunol; 1997 Apr; 54(1):21-9. PubMed ID: 9154454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.